Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death

Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is currently being tested in phase II clinical trials. We herein aimed to investigate t...

Full description

Saved in:
Bibliographic Details
Published in:Oncology research 2017-11, Vol.25 (9), p.1489-1494
Main Authors: Vetma, Vesna, Rožanc, Jan, Charles, Emilie M., Hellwig, Christian T., Alexopoulos, Leonidas G., Rehm, Markus
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Birinapant
Cell Death
Cell Death - drug effects
Cell Line, Tumor
Dacarbazine
Dacarbazine - administration & dosage
Dipeptides - administration & dosage
Dipeptides - pharmacology
Humans
Indoles - administration & dosage
Indoles - pharmacology
Melanoma
Melanoma - drug therapy
Melanoma - pathology
Mutation
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Synergy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is currently being tested in phase II clinical trials. We herein aimed to investigate the antitumor efficacy of dacarbazine in vitro, both as a single agent and in combination with birinapant, in melanoma cell lines. Covering clinically relevant drug concentration ranges, we conducted a total of 5,400 measurements in a panel of 12 human melanoma cell lines representing different stages of disease progression. Surprisingly, functionally relevant synergies or response potentiation in combination treatments was not observed, and only one cell line modestly responded to birinapant single treatment (approximately 16% cell death). Although we did not study the underlying resistance mechanisms or more complex in vivo scenarios in which dacarbazine/birinapant response synergies may still possibly manifest, our findings are nevertheless noteworthy because IAP antagonists were demonstrated to strongly enhance responses to DNA-damaging agents in cell lines of other cancer types under comparable experimental conditions in vitro.
ISSN:0965-0407
1555-3906
DOI:10.3727/096504017X14897145996933